The long noncoding RNA MALAT1 predicts human pancreatic islet isolation quality

Area of Science:

• Biotechnology
• Molecular Biology
• Regenerative Medicine

Background:

• Human islet isolation for Type 1 diabetes cell therapy is resource-intensive, with low success rates due to variable islet quality.
• Current methods lack reliable biomarkers to predict islet yield and transplantability before isolation.
• Identifying predictive biomarkers is crucial for optimizing islet isolation and improving clinical outcomes.

Purpose of the Study:

• To identify long non-coding RNAs (lncRNAs) that predict human islet quality and transplantability.
• To evaluate the potential of identified lncRNAs, specifically MALAT1, as biomarkers for clinical islet isolation.

Main Methods:

• Transcriptome sequencing of 18 human islet preparations stratified by quality (transplantable, intermediate, non-transplantable).
• Machine-learning algorithms (penalized regression) to identify differentially expressed lncRNAs.
• Validation of lncRNA findings in an independent set of 75 human islet preparations.
• Assessment of MALAT1 variants' predictive value in 19 pancreas samples, alone and combined with clinical scores.

Main Results:

• Ten lncRNAs were significantly associated with islet quality across all comparisons.
• Two variants of Metastasis-Associated Lung Adenocarcinoma Transcript-1 (MALAT1) were consistently identified.
• MALAT1 levels alone showed high specificity (AUC: 0.83) in predicting post-isolation islet quality.
• Combining MALAT1 with clinical scores (Edmonton Donor Points, BMI, NAIDS) improved predictive potential for transplantation.

Conclusions:

• MALAT1 serves as a promising biomarker for predicting human islet isolation quality.
• This biomarker enhances current donor selection criteria for clinical islet transplantation.
• The study provides valuable transcriptome data for islet quality assessment and biomarker discovery.